S. 148 · 118th Congress · Health
Stop STALLING Act
- IntroducedJan 30, 2023 Done
- CommitteeReported Mar 1, 2023 Done
- Senate floorDied Jan 3, 2025 Stopped here
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Congressional Research Service · summary of “Reported to Senate” version · Mar 1, 2023
Who lobbies on it
15 organizations · 111 filings · Q1 2023–Q4 2024One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Chamber of Commerce of the U.s.a.
8 of 8 quarters
“…S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and…”
$74.5M lobbying spend in 2024, all issuesQ4 2024 filing
-
Pharmaceutical Research and Manufacturers of America
8 of 8 quarters
“…S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1130: Health Care PRICE Transparency Act S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs…”
$31.0M lobbying spend in 2024, all issuesQ4 2024 filing
-
America's Health Insurance Plans Inc (ahip)
8 of 8 quarters
“…S. 148 - Stop STALLING Act - Sen. Klobuchar, Amy - pharmacy market approval processes S. 150 - Affordable Prescriptions for Patients Act of 2023 - Sen. Cornyn, John - pharmacy and prescription drug prices, prevent patent thickets S. 574 - Increasing Prescription Drug Competition Act - Sen. Hassan, Maggie - closure of…”
$11.8M lobbying spend in 2024, all issuesQ4 2024 filing
12 more organizations, every filingPROUpgrade
Organizations that named S. 148 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
5 actions · newest first- Mar 1, 2023Placed on Senate Legislative Calendar under General Orders. Calendar No. 21.
- Mar 1, 2023Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
- Feb 9, 2023Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Jan 30, 2023Read twice and referred to the Committee on the Judiciary.
Show all 5 actionsShow fewer
- Jan 30, 2023Introduced in Senate